BLUENERGIES LTD (BLU.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:BLU - CA0959221007 - Common Stock
BLU.CA Key Statistics, Chart & Performance
The current stock price of BLU.CA is 1.34 CAD. In the past month the price increased by 34%.
BLU.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 585.51M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 422.17M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 164.22M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 79.24M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 25 | 48.34M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.36M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 27.30M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 28.61M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.02M | ||
| MPH.CA | MEDICURE INC | N/A | 12.32M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.29M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M |
Related stock screener links
About BLU.CA
Company Profile
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Company Info
BLUENERGIES LTD
275 Armand-Frappier Blvd
Laval QUEBEC H7V 4A7 CA
CEO: Roberto Bellini
Employees: 74
Phone: 14506804500.0
BLUENERGIES LTD / BLU.CA FAQ
Can you describe the business of BLUENERGIES LTD?
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
What is the stock price of BLUENERGIES LTD today?
The current stock price of BLU.CA is 1.34 CAD.
What is the dividend status of BLUENERGIES LTD?
BLU.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BLU stock?
BLU.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the market capitalization of BLU stock?
BLUENERGIES LTD (BLU.CA) has a market capitalization of 169.91M CAD. This makes BLU.CA a Micro Cap stock.
BLU.CA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BLU.CA.
BLU.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |